摘要
目的探讨23G经结膜无缝合玻璃体切割系统(23GTVS)在玻璃体视网膜疾病中的应用,评估其疗效及安全性。方法回顾性分析2008年8月至2009年9月在我院行23G玻璃体切割术的患者42例(43眼)。其中,特发性黄斑裂孔16眼(37.2%),特发性黄斑前膜8眼(18.6%),玻璃体积血19眼(44.2%)。观察手术效果及时间、最佳矫正视力、眼压及术中、术后并发症等。术后随访1~10个月。结果所有病例均顺利完成手术,术后最佳矫正视力均有提高,术后1周矫正视力平均为0.88±0.54,末次随访为0.46±0.24,与术前比较差异均有显著统计学意义(均为P<0.01)。术后1周平均眼压为(14.0±4.5)mmHg(1kPa=7.5mmHg),接近术前水平。术中2眼套管滑脱,6眼结膜下轻微出血,3眼结膜下气泡;所有病例在随访期间无严重并发症发生。结论 23GTVS目前主要应用于黄斑疾病和玻璃体积血,术后恢复快,疗效好,并发症少,是一种安全有效的微创手术方法。
Objective To investigate the application of 23-gauge transconjunctival sutureless vitrectomy system in the treatment of vitreoretinopathy disease and evaluate its efficacy and safety.Methods A retrospective case of 23-gauge vitrectomy performed in 42 cases (43 eyes) in our hospital from August 2008 to September 2009.The diseases included idiopathic macular hole(16 eyes,37.2%),idiopathic macular epiretinal membrane(8 eyes,18.6%),vitreous hemorrhage(19 eyes,44.2%).The main observations were the surgical effects,surgical time,best corrected visual acuity,intraocular pressure,intraoperative and postoperative complications.The follow-up time was from 1 month to 10 months.Results All cases were successfully completed surgery and each surgical indication experienced a significant best corrected visual acuity improvement.The mean best corrected visual acuity was 0.88±0.54 at postoperative 1 week and 0.46±0.24 at the last follow-up;Compared with that before operation,there were all significant statistical differences(all P0.01).The mean intraocular pressure at postoperative 1 week was (14.0±4.5) mmHg (1 kPa=7.5 mmHg),closed to preoperative level.The intraoperative complications included intubation tube slippage in 2 eyes,little hemorrhage under conjunctiva in 6 eyes,bubble under conjunctiva in 3 eyes;No serious postoperative complication was observed during the follow-up time in all cases.Conclusion 23-gauge transconjunctival sutureless vitrectomy system with faster postoperative recovery,better curative effect and rare complications,is an effective and safe surgical technique in the management of macular diseases and vitreous hemorrhage currently.
出处
《眼科新进展》
CAS
北大核心
2010年第7期670-672,共3页
Recent Advances in Ophthalmology